Kynexis is a technology company.
Kynexis has raised $61.0M across 1 funding round.
Kynexis has raised $61.0M in total across 1 funding round.
Kynexis is a neuroscience-focused biotechnology company building a *precision medicine* approach to treat cognitive impairment associated with schizophrenia (CIAS) by advancing a first‑in‑class KAT‑II inhibitor and patient‑stratifying biomarkers[2][4].
High-Level Overview
Kynexis is a clinical-stage biotech startup (founded 2023) that develops precision therapeutics for brain diseases, with its lead program KYN‑5356 — a potent, selective KAT‑II inhibitor aimed at improving cognition in people with schizophrenia[2][4]. The company combines human genetics, biomarker-based patient stratification and large‑scale data to identify patients most likely to benefit from its mechanism, positioning itself in the neuropsychiatric/precision psychiatry niche[2][4]. Kynexis launched with a €57M Series A led by Forbion (with participation from Ysios Capital and Sunstone Life Science Ventures) and has operations in the Netherlands and a U.S. subsidiary in Cambridge, MA[2][4].
Origin Story
Kynexis was launched in November 2023 as a venture-backed spinout to translate decades of academic and industry research on the kynurenine pathway into a precision therapeutic for CIAS; the company was co‑founded by investors / life‑science incubators Forbion and Ysios Capital and assembled a leadership team with deep CNS drug‑development experience[2][3]. Its scientific roots include work by researchers such as Robert Schwarcz, whose lab helped pioneer the role of the kynurenine pathway in cognition and schizophrenia; KYN‑5356 was licensed exclusively from Mitsubishi Tanabe Pharma Corporation[4][2]. Early traction included securing the Series A financing (€57M) at launch and exclusive worldwide rights to the candidate, giving the company resources to move the program toward clinical development[2][3].
Core Differentiators
Role in the Broader Tech/Healthcare Landscape
Quick Take & Future Outlook
What's next: Near term priorities are advancing KYN‑5356 into clinical development (first‑in‑human / proof‑of‑concept studies) using biomarker‑driven patient selection and generating clinical readouts that validate both the mechanism and the stratification approach[2][4].
Key trends to watch: progress in biomarker/companion diagnostic development, regulatory receptivity to biomarker‑guided psychiatry trials, and early clinical signals on cognition endpoints in CIAS will determine strategic momentum[2][4].
How influence might evolve: A positive clinical proof‑point would position Kynexis as a leader in precision psychiatry and could catalyze further investment into mechanism‑based CNS programs; conversely, failure to demonstrate biomarker‑linked efficacy would highlight the persistent challenges of translating neuroscience into clinical benefit. The company’s strong Series A backing and exclusive asset license give it runway to test the approach in human studies before needing additional proof to scale[2][3].
Core facts cited above are drawn from Kynexis’s company announcements and profile at launch and industry coverage describing its Series A, lead candidate (KYN‑5356), scientific rationale and founding/leadership details[2][4][1].
Kynexis has raised $61.0M in total across 1 funding round.
Kynexis's investors include Max Klement, Cambridge Innovation Capital, Forbion.
Kynexis has raised $61.0M across 1 funding round. Most recently, it raised $61.0M Series A in November 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2023 | $61.0M Series A | Max Klement, Cambridge Innovation Capital, Forbion |